Nevertheless, they detected the CLL-1 expression only in de novo CD34+ Non-M3 AML, while we evaluated the CLL-1 expression in nonselected patients including de novo and relapsed AML, further supporting its high value in prognosis. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.